Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1998-01-01
|
| Series: | Mediators of Inflammation |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09629359891027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g). In mild to moderately active ulcerative colitis, studies also indicate that higher dosages might be more effective in inducing remission. Dose-comparing studies in Crohn's disease are even more sparse, but the available results indicate higher efficacy at higher dose levels. |
|---|---|
| ISSN: | 0962-9351 1466-1861 |